Sphera Global Healthcare Fund
Sphera Global Healthcare Fund is a long/short equity fund that is focused on the global pharmaceutical and biotech industries.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Sphera Global Healthcare Fund Information
Geographic Data
Address: 9th Floor
City: New York
State: NY
Zip: 10017
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Sphera Global Healthcare Management (Investment Manager) is a partnership between Mr. Mori Arkin, former vice chairman of Perrigo (Nasdaq ticker:PRGO, a world leader in generic and OTC drugs), and of Sphera Funds Management. It is a long/short equity fund that is focused on the global pharmaceutical and biotech industries. The Investment Manager’s objective is to generate consistent and attractive long term returns exceeding the industry while maintaining disciplined risk management. With a highly experienced and cohesive multidisciplinary team, the Fund’s competitive advantage is evident in three key areas: • Having a rigorous, fundamental, focused and comprehensive approach to healthcare research. • Investment committee co- led by an industry veteran with a track record of building a pharmaceutical company. • Unique and unbiased investment approach generated in part from access to massive flow of R &a;D, innovation and top tier human capital in Israel.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2020 | Yumanity Therapeutics | Venture Round | 0 |
| 8/2020 | ESSA Pharma | Post-IPO Equity | 0 |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 7/2019 | Frontier Medicines | Series B | 88.5M |
| 10/2020 | LianBio | Series A | 0 |
| 3/2015 | aTyr Pharma | Series E | 76M |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 7/2020 | Cerevel Therapeutics | Post-IPO Equity | 0 |
| 11/2015 | ObsEva | Series B | 60M |
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 8/2020 | Chinook Therapeutics | Private Placement | 106M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
| 3/2021 | Immune-Onc Therapeutics | Series B | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 9/2021 | BioAtla | Post-IPO Equity | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 3/2021 | Immune-Onc Therapeutics | Series B | 0 |
| 1/2021 | Werewolf Therapeutics | Series B | 0 |
| 12/2020 | Yumanity Therapeutics | Venture Round | 0 |
| 10/2020 | LianBio | Series A | 0 |
| 9/2020 | I-Mab Biopharma | Post-IPO Equity | 0 |
| 8/2020 | Chinook Therapeutics | Post-IPO Equity | 0 |
| 8/2020 | ESSA Pharma | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
